BOVILIS® VISION® 7
WITH SPUR®*
Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid
Product Description
Shown to be effective for the vaccination of healthy cattle and sheep against disease caused by Clostridium chauvoei (Blackleg), Cl. Septicum (Malignant edema), Cl. novyi (Black disease), Cl. sordellii, Cl. perfringens Types C and D (Enterotoxemia).
Indications
This product has been shown effective for the vaccination of healthy cattle and sheep against Clostridium chauvoei, C. septicum, C. novyi, C. sordellii, C. perfringens Types C & D. This product was licensed prior to the requirement to establish a minimum age for use. Duration of immunity has not been established.
Diseases
- Clostridium sordellii
A Game-changing Vaccine
Understanding immunology and innovation are critical to addressing emerging diseases and industry challenges through new and improved vaccines. Merck Animal Health has a history of finding a better way forward through vaccine advancements, and today offers one of the most complete vaccine portfolios. Learn about BOVILIS VISION from members of the team who brought it to market.
Dosage
Shake well and administer a single 2 mL dose aseptically by subcutaneous route. Repeat the dose in 3 – 4 weeks. For advice on revaccination frequency, contact your veterinarian.
Supplied
1 x 20mL (10 doses)
1 x 100mL (50 doses)
1 x 500mL (250 doses)
Preservatives
Contains formaldehyde as a preservative.
Storage
Store at 2°-8°C (35°-46°F). Do not freeze. Use entire contents when first opened.
Safety
Do not mix with other products. Do not vaccinate within 21 days before slaughter. This product has not been tested in pregnant animals. If allergic reaction occurs, treat with epinephrine. In case of human exposure, contact a physician.
FOR ANIMAL USE ONLY.
Contact
U.S. only: Merck Animal Health livestocktechsrvc@merck-animal-health.com or call 1-800-211-3573
For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov
For additional information, please see the product label.
References
- *Adjuvant-Intervet’s Proprietary Technology.
Go To United States
Algeria
Argentina
Australia
Austria
Bahrain
Belgium (Dutch)
Brazil
Canada (English)
Chile
Colombia
Croatia
Czech Republic
Denmark
Ecuador
Egypt
Finland
France
Germany
Greece
Hungary
India
Indonesia
Iraq
Ireland
Israel
Italy
Japan
Jordan
Kuwait
Lebanon
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Norway
Oman
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russian Federation
Saudi Arabia
South Africa
South Korea
Spain
Sweden
Switzerland (French)
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Yemen
Global